BNTX · BioNTech SE

BioNTech SE reported a challenging first quarter of 2026, characterized by a significant contraction in revenue and an expanded operating loss. Total revenues fell to €118.1 million from €182.8 million in the prior year period, a decline attributed to the post-pandemic normalization of COVID-19 vaccine demand. Despite the revenue drop, the company maintained its strategic focus on pipeline development, with R&D expenses increasing to €557.0 million. This sustained investment, combined with lower top-line contributions, resulted in an operating loss of €677.5 million, a substantial increase from the €534.1 million loss recorded in Q1 2025. The net loss for the quarter widened to €531.9 million, or €2.10 per share.

Liquidity remains a strong point for the company. Cash and cash equivalents increased to €9.94 billion as of March 31, 2026, up from €7.68 billion at the end of December 2025. This increase was primarily driven by net cash inflows from investing activities totaling €2.65 billion, largely resulting from the maturity of financial assets, which offset the €421.0 million used in operating activities. The robust cash position provides BioNTech with a substantial runway to fund its ongoing clinical trials and operational expansion in oncology and infectious disease programs without immediate financing pressures.